|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Dilated cardiomyopathy caused by lamin A/C gene (LMNA) mutation is complicated with atrioventricular (AV) conduction disturbances, malignant ventricular arrhythmias, and progressive severe heart failure.
|
31060954 |
2019 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Sudden death and heart failure because of left ventricular dysfunction are important causes of mortality, particularly in those patients that have the LMNA mutation.
|
30518714 |
2019 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thus, global errors in chromosomal compartmentation are not the primary pathogenic mechanism in heart failure due to lamin A/C haploinsufficiency.
|
31395619 |
2019 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cardiomyopathy caused by lamin A/C gene (LMNA) mutations (hereafter referred as LMNA cardiomyopathy) is an anatomic and pathologic condition associated with muscle and electrical dysfunction of the heart, often leading to heart failure-related disability.
|
30053027 |
2018 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cardiomyopathy caused by lamin A/C gene (LMNA) mutations (hereafter referred as LMNA cardiomyopathy) is an anatomic and pathologic condition associated with muscular and electrical dysfunction of the heart, often leading to heart failure-related disability.
|
29982513 |
2018 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the LMNA gene are a common cause (6-8%) of dilated cardiomyopathy (DCM) leading to heart failure, a growing health care problem worldwide.
|
29702688 |
2018 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Most individuals with cardiomyopathy associated with variants of the LMNA (lamin A) gene present with cardiac conduction abnormalities followed by dilated cardiomyopathy and cardiac failure; some also have skeletal muscle weakness.
|
29741282 |
2018 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The novel LMNA nonsense mutation c.544C>T causes a severe arrhythmogenic phenotype manifesting with high incidence of SCD in most patients; and in one sub-family, a distinct phenotype with fast progressing heart failure, indicating the need for early consideration of ICD-implantation and listing for heart-transplantation.
|
29947763 |
2018 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lamin A/C gene mutations can be associated with cardiac diseases, usually referred to as 'cardiolaminopathies' characterized by arrhythmic disorders and/or left ventricular or biventricular dysfunction up to an overt picture of heart failure.
|
30130999 |
2018 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Given the clinical impact of LMNA cardiomyopathies, understanding lamin function will fulfill a clinical need and will lead to advancement in the treatment of heart failure.
|
29432544 |
2018 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cardiomyopathy caused by lamin A/C gene (LMNA) mutations (hereafter referred as LMNA cardiomyopathy) is characterized by cardiac conduction abnormalities and left ventricular systolic dysfunction predisposing to heart failure.
|
28069793 |
2017 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cardiomyopathy caused by lamin A/C gene mutations (LMNA cardiomyopathy) is characterized by increased myocardial fibrosis, which impairs left ventricular relaxation and predisposes to heart failure, and cardiac conduction abnormalities.
|
27131347 |
2016 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although FTD is not a constant pathological feature of LMNA-myopathy, we should consider the possibility of LMNA-myopathy whenever a diagnosis of CFTD is made and take steps to prevent cardiac insufficiency.
|
24642510 |
2014 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
LMNA cardiomyopathy has an aggressive clinical course with higher rates of deadly arrhythmias and heart failure than most other heart diseases.
|
21810905 |
2011 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
They further provide proof of principle for ERK inhibition as a therapeutic option to prevent or delay heart failure in humans with Emery-Dreifuss muscular dystrophy and related disorders caused by mutations in LMNA.
|
18927124 |
2009 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dilated cardiomyopathies caused by LMNA gene defects are highly penetrant, adult onset, malignant diseases characterized by a high rate of heart failure and life-threatening arrhythmias, predicted by New York Heart Association functional class, competitive sport activity, and type of mutation.
|
18926329 |
2008 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our in vivo and in vitro results question the relationship of causality between LMNA mutations and the development of heart failure in some DCM patients and therefore, the reliability of genetic counselling.
|
16061563 |
2005 |